Company Focus
Novo Nordisk
Latest Novo Nordisk News
Pharmaceutical
Novo Nordisk late Thursday announced that it will advance subcutaneous (SC) and oral amycretin into Phase III development in weight management based on completed clinical studies and feedback received from regulatory authorities. 13 June 2025
Related News
Insights
Company Spotlight
A private, clinical-stage biopharmaceutical company committed to developing best-in-class, novel therapy for the treatment of hypertension.
Latest News & Features of interest to Novo Nordisk
Pharmaceutical
Syndax Pharmaceuticals, a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced new data from the pivotal AUGMENT-101 trial of Revuforj (revumenib), the company’s first-in-class menin inhibitor, in patients with relapsed or refractory (R/R) mutant NPM1 (mNPM1) and NUP98-rearranged (NUP98r) acute myeloid leukemia (AML). 12 June 2025
Biotechnology
US antivirals specialist Gilead Sciences’ Kite, unit today presented the latest results that demonstrate a 79% overall response rate (ORR) and 74% overall survival (OS) at six months follow-up, for Yescarta (axicabtagene ciloleucel) as second-line treatment for relapsed/refractory (R/R) large B-cell lymphoma (LBCL), from the largest real-world study in this patient population. 12 June 2025
Biosimilars
South Korea’s biosimilar drug developer Samsung Bioepis today presented the long-term safety data of Epysqli (eculizumab; SB12), a biosimilar to AstraZeneca’s Soliris, in paroxysmal nocturnal hemoglobinuria (PNH) at the European Hematology Association (EHA) Congress 2025 held at Milan, Italy from June 12 to 15. 12 June 2025
Biotechnology
French biotech Enterome has secured $19 million in private funding to accelerate development of its OncoMimics immunotherapy platform, as it continues to show encouraging early signs of clinical activity across both solid and blood cancers. 12 June 2025
Pharmaceutical
Danish pharma major Novo Nordisk and privately-held Californian firm Deep Apple Therapeutics have announced a research collaboration and exclusive worldwide license agreement. 11 June 2025
Pharmaceutical
USA-based Insmed Incorporated closed Tuesday’s trading up by more than a third. 11 June 2025
Biotechnology
South Korean biotech AriBio Co, specializing in neurodegenerative diseases, and a Swiss pharmaceutical company Acino, part of Arcera, a global life sciences company based in Abu Dhabi, announced an exclusive licensing and commercialization, and supply agreements for AR1001, an investigational oral therapy for Alzheimer’s disease. 11 June 2025
Biotechnology
Angelini Ventures has joined a syndicate of European life sciences investors to back Elkedonia, a French biotech developing a new class of neuroplastogens to treat depression and other neuropsychiatric conditions. 11 June 2025
Pharmaceutical
China-based biotech Innogen is making a strategic pivot toward international visibility following regulatory clearance of its first-in-class, ultra-long-acting GLP-1 receptor agonist for type 2 diabetes, alongside a move to go public on the Hong Kong Stock Exchange. 11 June 2025
Pharmaceutical
Last month, the Future Health Report was presented at the World Health Assembly in Geneva, Switzerland. 10 June 2025
Latest In Brief for Novo Nordisk
Biotechnology
The benefits from Eli Lilly’s Kisluna (donanemab) remain too small to justify the additional cost to the National Health Service (NHS), said the UK health technology assessor the National Institute for Health and Care Excellence (NICE), which also rejected Japanese drugmaker Eisai and US biotech Biogen Leqembi (lecanemab) for the same reason. 19 June 2025
Latest Related Ones To Watch News
US pharma major Eli Lilly (today announced a definitive agreement to acquire Verve Therapeutics, a Boston-based clinical-stage company developing genetic medicines for cardiovascular disease, sending Verve’s shares up 77.7% to $11.15 in premarket trading. 17 June 2025
16 June 2025
Related Ones to Watch Companies
Refine Search
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze